Headline News about Gilead Sciences
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
Via Benzinga
Exposures
Product Safety
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
February 23, 2024
Via Benzinga
Via Talk Markets
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
Via Benzinga
Topics
Stocks
Exposures
US Equities
Via Benzinga
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Via Benzinga
Exposures
Product Safety
Gilead Sciences Stock Approaches Daily Buying Area
February 12, 2024
Via Talk Markets
Exposures
COVID-19
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Via Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.